Pencil Beam Scanning (PBS) in Radiotherapy of Malignant Lymphomas
|
|
- Martina Hoover
- 5 years ago
- Views:
Transcription
1 Pencil Beam Scanning (PBS) in Radiotherapy of Malignant Lymphomas J. Kubeš PTC Prague, Czech Rep.
2 Why proton beam therapy Why protons? - Have Bragg peak and they stop in the tissue - Radiobiological effectiveness is similar Bragg's peak is energy-dependent. This energy can be precisely regulated Better dose distribution in the body Dose 40-50% Photons Protons Photons 60 Gy 40% dose 2,400 X-rays of the skull
3 Proton therapy technology First clinical use 1953 Technology sophisticated from 2011 Cyclotron Magnetic optics Gantry
4 Pencil beam scanning Technology available from 2011 A fundamental change in proton technology Better dose distribution Greater and more complicated targets Smaller neutron contamination
5 Equipment Proton beam - Cyclotron IBA Proteus MeV nominal beam energy IGRT - Verisuite - VisionRT - Robotic couch - DynR Imaging - 2x MRI - 2x CT - PET/CT Clinical oncology Urology ORL Cooperation with: - Czech and Slovakia comprehensive cancer centers - Charles University, Czech Technical University, Academy of Science
6 Malignant lymphomas Malignant lymphomas 1) Comprehensive and extensive target volumes 2) Young patients 3) High curability rate 4) Late and very late effects of photon techniques - Cardiotoxicity - RIHD - Ischemic heart disease - Pneumotoxicity - Secondary cancer 3D CRT heart dose! IMRT - lung dose, breast dose! Better tool PBS(?) Schellong et al., 2010; Hull et al., 2003; Heidenreich et al., 2003; Brusamolino et al., 2006; Harbron et al., 2013
7 Cardiotoxicity Hahn E. described 44 cardiac events in 125 HL patients. Risk was correlated with heart dose and heart vessels dose. Darby et al., 2013 Popuation study 2,168 women Treatment Heart Dmean = 4.7 Gy Risk increases with 7.4% per Gy Without threshold.
8 Malignant lymphomas
9 Secondary malignancies Cellai et al. IJROBP (2001) described 14.9% incidence of SM in 20 years. In a lifetime approximately 42 of 100 people will be diagnosed with cancer. Approximately one cancer (star) per 100 people could result from a single exposure to 0.1 Sv of low-let radiation above background.
10 Cardiotoxicity and secondary malignancies are significant complications of radiotherapy of lymphomas Probability is dose-dependent Proton radiation can significantly reduce doses to the heart and integral dose
11 1 Which malignant lymphomas? Maximum utilization of proton beam features: - Sharp dose gradient - Stopping at a defined depth - Significant reduction of dose Significant dosimetric benefit - Hodgkin lymphoma/nhl - Mediastinal forms - Residual mediastinal mass Women, 25 years old, Hodgkin lymphoma st. IIBE Residual PET + mediastinal -
12 Malignant Lymphomas PROTON THERAPY FOR THE MANAGEMENT OF HODGKIN AND NON-HOGKIN LYMPHOMAS INVOLVING THE MEDIASTINUM: GUIDELINES FROM THE INTERNATIONAL LYMPHOMA RADIATION ONCOLOGY GROUP (ILROG) Bouthaina Shbib Dabaja, Bradford S. Hoppe, John P. Plastaras, Wayne Newhauser, Katerina Rosolova, Stella Flampouri, Radhe Mohan, N. George Mikhaeel, Youlia Kirova, Karin Dieckmann, Lena Specht, Joachim Yahalom.
13 Problem - movement
14 Effects of movement Criteria gamma 3mm, 3% γ<1 [%] γ<1,5 [%] Average gamma Max gamma Gating Without gating
15 Motion management Repainting Gating Tumor tracking Deep inspiration breathold Movement up to 1 cm! Movement still present! Promising, but technology still not available! Stopping of movement, possible solution
16 Motion management - DIBH Dyn R
17 Reproducibility Fusion of two DIBH CT scans (HL, IS RT)
18 Robustness of deep inspiration 3 patients - CT in the upper or lower part of deep inspiration Comparison of differences in WET for 5 points for each CT series Calculation in Python
19 PET/CT check of dose distribution Virtual dose distribution CALCULATED In vivo dose control REAL Activation of tissue PET/CT immediately after fraction (in 10 min) Spatial control Detection of activation outside of the target volume
20 Clinical experiences at PTC Prague Number of Lymphoma patients D CT and repainting 2015 DIBH (in combination with repainting, if necessary)
21 Proton Radiotherapy for Mediastinal Hodgkin Lymphoma: Single Institution Experience Dědečková et al., 10th ISHL, Cologne, 2016
22 Characteristics of patient group (n=35) Males/Females [pts.] 10/25 Age at the time of RT median [years] 27 (13-59 ) RT volume [pts.] Involved field 9 Residual disease 11 Involved site 15 Follow-up median [months] 9.9 ( ) RT on PET neg/pet positive disease [pts.] 25/10 RT in DIBH/FB [pts.] 17/18 Median dose [GyE] 30 ( ) All patients were irradiated via pencil beam scanning (PBS) technique Dědečková et al., 10th ISHL, Cologne, 2016
23 Dosimetric parameters (n=35) PTV volume [cm3] 1,207.6 ( ,252.8) Heart Dmean [Gy] 6.6 ( ) Lungs bilat. Dmean [Gy] 4.9 ( ) Lungs bilat. V5 [%] 30 ( ) Lungs bilat. V20 [%] 22.3 ( ) L mammary gland Dmean [Gy] 1.3 (0-6.8) R mammary gland Dmean [Gy] 0.9 (0-2.5) L mammary gland V4 [%] 11.6 ( ) R mammary gland V4 [%] 10.2 ( ) Oesophageus Dmean [Gy] 17.3 (0-30.8) Spinal Cord Dmax 2% [Gy] 5.2 (0-21) Dědečková et al., 10th ISHL, Cologne, 2016
24 Acute toxicity (CTCAE v4.0) Pharyngeal mucositis grade 2: 9% grade 1: 63% Leucopenia grade 3: 3% grade 2: 6% Radiodermatitis grade 2: 3% grade 1: 40% Pleuritic pain grade 1: 3% NO CASE of radiation pneumonitis or Lhermitt s syndrome NO PATIENT required growth factors or hemosubstitution during RT Dědečková et al., 10th ISHL, Cologne, 2016
25 Relaps probability Treatment results Time to relaps (Kaplan Meier) Time (months) Total observed Total failed Total censored patients (100%) achieved local control 2 pts (6%) progressed out of the target volume (distal regions) 34 pts (97%) are in complete remission (1 pt after alo-sct) 1 pt (3%) has progressive disease on salvage therapy Dědečková et al., 10th ISHL, Cologne, 2016
26 Summary on protons for mediastinal Hodgkin lymphoma Promising and safe option for a majority of patients Low acute toxicity profile and a potential to decrease the risk of significant late toxicity Should be considered in all HL patients indicated for mediastinal RT ( first of all, young patients with long life expectancy) or re-irradiation
27 Case 1 Mediastinal Hodgkin Lymphoma Female, 44 years - Hodgkin lymphoma, NS, st. IIB, dg. 5/2016, 1 Risk factor PTV Dmean 27,85 - Initial involvement: Lung (R+L) mediastinal Dmean mass x28 mm, Heartpretracheal Dmean mass 39x30 3,17 mm, mediastinal Spinal cord lymf Dmax nodes 18 mm, left 1.7 axilar and Breast supraclavicular R Dmean lymph nodes x escal. BEACOPP+2x ABVD Breast L Dmean Metabolic CR 9/ /2016 RT IS 30 Gy/15fr Organ at risk Parameter Dose Gy Standard case significant reduction of heart dose, lung dose, reduction of breast dose - Last follow up: 3/ CR - without toxicity
28 Case 2 Mediastinal Hodgkin Lymphoma Male, 23 years - Hodgkin lymphoma, Organ at risk NS, Parameter st. IIB, dg. 11/2017, Dose Gy 2 Risk factors - Initial involvement: PTV mediastinal Dmean mass 72x mm, including lower mediastinum Lung (R+L) precordialy, Dmean supraclavicular 5.26 and neck lymph nodes Heart Dmean 5.8-2x ABVD Spinal cord Dmax Interim PET/CT Esophageus negative Dmean x ABVD - 5/2018 RT IS 30 Gy/15fr Most suitable case for protons - significant reduction of heart dose, lung dose - Last follow up: 9/ episode of asymptomatic radiation pnemonitis - CR based on PET/CT 8/2018
29 Case 3 Subdiaphragmatical Non-Hodgkin Lymphoma Organ at risk Parameter Dose Gy Male, 69 years PTV Dmean Non Hodgkin B-lymphoma, DLBCL, dg , st.iias, - Liver Dmean 6.42 Initial involvement: liver hilus, spleen - stp 6X r-chop+2x Kidney R R Dmean PR on PET/CT Kidney(PET+ L liver Dmean involvement, 3.57 CR spleen) - 7/2018 RT Spinal to PET+ cordresidual Dmax disease 36 Gy/18fr 26.6 Feasible with protons - significant reduction of liver, kidney, abdominal cavity dose
30 Female, 26 Organ yearsat risk Parameter Dose Gy - Non Hodgkin PTV B-lymphoma, Dmean DLBCL, CD 20+, aaipi 2 (LDH, PS), RF (mediastinal bulk, Ki67 80%, stk) dg. 3/2017, st.iia, Lung (R+L) Dmean Initial involvement mediastinal mass 142x88x197 mm, lymph nodes mediastinal Heart Dmean stp. 2x Spinal R-PACEBO cord from Dmax 3/2017, restaging Esophageus after 2.cyklus Dmean PR R-IVAM from 5/ R-HAM priming from , sběr PSC, - 3x R-PACEBO - TrnsplantationRefractory, of PBSC bulky mediastinal - PET/CT : persistent/progressive disease in mediastinal mass - Radiotherapy to the PET+ residual disease 50 Gy/25fr 1/ Allo-SCT 3/2018-9/2018 PR-CR Case 4 Mediastinal Non-Hodgkin Lymphoma, highly pretreaed disease almost impossible to treat to such doses with photons. Probably CR after alo-sct
31 Case 5 Non-Hodgkin Lymphoma, highly pretreaed, pleural involement Organ at risk Parameter Dose Gy PTV Dmean Male, 37 years - Non Hodgkin Lung (R+L) T-lymphoblastic Dmeanlymphoma, st.ivb, - SeveralHeart lines of chemotherapy Dmean - Allo-SCT including TBI - PET + residual Spinal cord disease in Dmax mediastinum and pleural cavity Esophageus Dmean - Radiotherapy to the PET+ residual disease 36 Gy/18 fr 8/2013-5/2016 CR, without significant toxicity Refractory disease, pleural involvement, after TBI considered like palliative treatment, 3 years after CR
32 Conclusion Adaptive radiotherapy with PBS for Head and neck cancer is feasible approach with low toxicity rate and promising effectivity Demografické parametry PBS radiotherapy with gating in DIBH is feasible approach for malignant lymphomas with significantly better dosimetry than photon radiotherapy
33 Thank you for attention!
Non-Hodgkin s Lymphomas Version
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Non-Hodgkin s Lymphomas Version 2.2015 NCCN.org Continue Principles of Radiation Therapy PRINCIPLES OF RADIATION THERAPY a Treatment with
More informationASTRO econtouring for Lymphoma. Stephanie Terezakis, MD
ASTRO econtouring for Lymphoma Stephanie Terezakis, MD Disclosures No conflicts to disclose 1970 Total Lymphoid Irradiation (TLI) 1995 Involved-Field Radiotherapy (IFRT) 2008 Involved Node Radiotherapy
More informationRole of radiotherapy in the treatment of lymphoma in Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark
Role of radiotherapy in the treatment of lymphoma in 2017 Lena Specht MD DMSc Professor of Oncology Rigshospitalet, University of Copenhagen Denmark Disclosures Member of Advisory Board and Principal Investigator,
More informationDr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA???
Dr. Noelle O Rourke Beatson Oncology Centre, Glasgow RADIOTHERAPY FOR LYMPHOMA??? History of Radiotherapy 1895 Rontgen describes X-rays 1896 Becquerel radioactivity 1905 Radiation is used to treat tumours
More informationOne, the UK RAPID trial, including patients with early stage disease stage 1 and 2A nonbulky.
Martin Hutchings, MD, PhD Department of Hematology The Finsen Centre, National Hospital Copenhagen University Hospital Copenhagen, Denmark Welcome to Managing Hodgkin Lymphoma. My name is Martin Hutchings.
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationFuture upcoming technologies and what audit needs to address
Future upcoming technologies and what audit needs to address Dr R.I MacKay History of audit Absolute dose - Simple phantom standard dose measurement Point doses in beams - Phantoms of relatively simple
More informationIMRT - the physician s eye-view. Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia
IMRT - the physician s eye-view Cinzia Iotti Department of Radiation Oncology S.Maria Nuova Hospital Reggio Emilia The goals of cancer therapy Local control Survival Functional status Quality of life Causes
More informationLugano classification: Role of PET-CT in lymphoma follow-up
CAR Educational Exhibit: ID 084 Lugano classification: Role of PET-CT in lymphoma follow-up Charles Nhan 4 Kevin Lian MD Charlotte J. Yong-Hing MD FRCPC Pete Tonseth 3 MD FRCPC Department of Diagnostic
More informationState of the Art Radiotherapy for Pediatric Tumors. Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center
State of the Art Radiotherapy for Pediatric Tumors Suzanne L. Wolden, MD Memorial Sloan-Kettering Cancer Center Introduction Progress and success in pediatric oncology Examples of low-tech and high-tech
More informationRadiation and Hodgkin s Disease: A Changing Field. Sravana Chennupati Radiation Oncology PGY-2
Radiation and Hodgkin s Disease: A Changing Field Sravana Chennupati Radiation Oncology PGY-2 History of Present Illness 19 yo previously healthy male college student began having pain in his R shoulder
More informationPresent status and future of Proton beam therapy
Present status and future of Proton beam therapy Description At present, the types of proven treatment for cancer are surgery, radiotherapy, and chemotherapy. Depending on the characteristics of cancer
More informationSarcoma and Radiation Therapy. Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington
Sarcoma and Radiation Therapy Gabrielle M Kane MB BCh EdD FRCPC Muir Professorship in Radiation Oncology University of Washington Objective: Helping you make informed decisions Introduction Process Radiation
More informationRadiotherapy in DLCL is often worthwhile. Dr. Joachim Yahalom Memorial Sloan-Kettering, New York
Radiotherapy in DLCL is often worthwhile Dr. Joachim Yahalom Memorial Sloan-Kettering, New York The case for radiotherapy Past: Pre-Rituximab randomized trials Present: R-CHOP as backbone, retrospective
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More informationThe Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD. The Promise of Protons
The Economic Club of Florida Tallahassee August 13, 2018 Nancy P Mendenhall, MD The Promise of Protons The Promise of Protons Cancer and radiation therapy The promise of protons UFHPTI: missions and operation
More informationPTCOG 46. Educational Workshop Session IV. Head & Neck CLINICAL. J. Mizoe (NIRS, Japan)
PTCOG 46 Educational Workshop Session IV CLINICAL Head & Neck J. Mizoe (NIRS, Japan) Photon X-Ray γ-ray Fast Neutron Non-Charged Radiation Electron Proton Helium Light Ion Heavy Particle Carbon Neon Argon
More informationClinical Report for Wanjie Proton Therapy Center. Li Jiamin, MD Wanjie Proton Therapy Center
Clinical Report for Wanjie Proton Therapy Center Li Jiamin, MD Wanjie Proton Therapy Center General Information Wanjie Proton Therapy Center was founded in June 2001 The first patient was treated in Dec.
More informationThe role of chemoradiotherapy in GE junction and gastric cancer. Karin Haustermans
The role of chemoradiotherapy in GE junction and gastric cancer Karin Haustermans Overview Postoperative chemoradiotherapy Preoperative chemoradiotherapy Palliative radiation Technical aspects Overview
More informationA Practical Guide to PET adapted Therapy for Hodgkin Lymphoma
Hello. My name is Peter Johnson. I am a Professor of Medical Oncology in Southampton in the UK and I am speaking today on behalf of Managing Hodgkin Lymphoma, and particularly, I am going to talk about
More informationHodgkin Lymphoma: Umberto Ricardi
Hodgkin Lymphoma: Radiation Volumes Umberto Ricardi Università di Torino The changing role of RT in the cure of HL From Maximal use as a single agent To Combination of chemotherapy and full dose-full volume
More informationClinical Education A comprehensive and specific training program. carry out effective treatments from day one
Proton Therapy Clinical Education A comprehensive and specific training program carry out effective treatments from day one Forewarned is forearmed Although over 100,000 patients have been treated in proton
More informationIAEA RTC. PET/CT and Planning of Radiation Therapy 20/08/2014. Sarajevo (Bosnia & Hercegovina) Tuesday, June :40-12:20 a.
IAEA RTC PET/CT and Planning of Radiation Therapy Sarajevo (Bosnia & Hercegovina) Tuesday, June 17 2014 11:40-12:20 a.m María José García Velloso Servicio de Medicina Nuclear Clínica Universidad de Navarra
More informationClinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience
Clinical Results of Carbon Ion Radiotherapy: The Heidelberg Experience Stephanie E. Combs, MD Department of Radiation Oncology University of Heidelberg, Germany Carbon ion RT at GSI Active beam delivery
More information8/3/2016. Implementation of Pencil Beam Scanning (PBS) Proton Therapy Treatment for Liver Patients. Acknowledgement. Overview
Implementation of Pencil Beam Scanning (PBS) Proton Therapy Treatment for Liver Patients Liyong Lin, PhD, Assistant Professor Department of Radiation Oncology University of Pennsylvania Acknowledgement
More informationProtocol of Radiotherapy for Head and Neck Cancer
106 年 12 月修訂 Protocol of Radiotherapy for Head and Neck Cancer Indication of radiotherapy Indication of definitive radiotherapy with or without chemotherapy (1) Resectable, but medically unfit, or high
More informationStereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.
Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V. Hepatocellular carcinoma (HCC), is a major health problem worldwide.
More informationRadiation Therapy in SCLC. What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department
Radiation Therapy in SCLC What is New? Prof. Dr. Hoda Abdel Baky El Bakry Cairo Cancer Institute Radiation Oncology Department Background Overview Small Cell Lung cancer constitute about 15 % of all newly
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationAndrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center Seungtaek Choi, MD Assistant Professor Department tof fradiation
More informationFROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE. Geoffrey S. Ibbott, Ph.D. June 20, 2017
FROM ICARO1 TO ICARO2: THE MEDICAL PHYSICS PERSPECTIVE Geoffrey S. Ibbott, Ph.D. June 20, 2017 1 DISCLOSURES My institution holds Strategic Partnership Research Agreements with Varian, Elekta, and Philips
More informationCharacterization and implementation of Pencil Beam Scanning proton therapy techniques: from spot scanning to continuous scanning
Characterization and implementation of Pencil Beam Scanning proton therapy techniques: from spot scanning to continuous scanning Supervisors Prof. V. Patera PhD R. Van Roermund Candidate Annalisa Patriarca
More informationThe role of Radiation Oncologist: Hi-tech treatments for liver metastases
The role of Radiation Oncologist: Hi-tech treatments for liver metastases Icro Meattini, MD Radiotherapy-Oncology Unit AOU Careggi Hospital Florence University, Italy Liver Metastases - Background The
More informationDOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES
DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE
More informationIAEA Pediatric Radiation Oncology Training Dr Laskar Version 1 June 2009 RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE
RADIATION THERAPY FOR PEDIATRIC HODGKIN S DISEASE THOMAS HODGKIN 1832 On Some Morbid Appearances of the Absorbent Glands & Spleen GLOBAL INCIDENCE Region Cases per 100,000 children United States 0.5 European
More informationOut-of-field dosimetry in radiotherapy for input to epidemiological studies. Roger Harrison
MELODI 7th Workshop, 9 11 November 2015 Helmholtz Zentrum München Next Generation Radiation Protection Research Out-of-field dosimetry in radiotherapy for input to epidemiological studies Roger Harrison
More informationInnovative RT SBRT. The variables with REQ in superscript are required.
The variables with REQ in superscript are required. The variables with a are single-select variables; only one answer can be selected. The variables with a are multi-select variables; multiple answers
More informationQuestions may be submitted anytime during the presentation.
Understanding Radiation Therapy and its Role in Treating Patients with Pancreatic Cancer Presented by Pancreatic Cancer Action Network www.pancan.org August 18, 2014 If you experience technical difficulty
More informationOverview. Proton Therapy in lung cancer 8/3/2016 IMPLEMENTATION OF PBS PROTON THERAPY TREATMENT FOR FREE BREATHING LUNG CANCER PATIENTS
IMPLEMENTATION OF PBS PROTON THERAPY TREATMENT FOR FREE BREATHING LUNG CANCER PATIENTS Heng Li, PhD Assistant Professor, Department of Radiation Physics, UT MD Anderson Cancer Center, Houston, TX, 773
More informationImage Guided Proton Therapy and Treatment Adaptation
Image Guided Proton Therapy and Treatment Adaptation www.hollandptc.nl d.r.schaart@tudelft.nl Cancer in The Netherlands About 1 in 3 people get cancer in some stage of their life 86.800 new cancer patients
More informationInnovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy. Sue S. Yom, M.D., Ph.D.
Innovations in Radiation Therapy, including SBRT, IMRT, and Proton Beam Therapy Sue S. Yom, M.D., Ph.D. Disclosures Genentech: advisory, research support ImClone: research support Plexxikon: research support
More informationStatus of H 1 and C 12
Status of H 1 and C 12 Herman Suit No Conflict of Interest 1 Goal of a New Treatment Modality Tumor Control Probability or No in Complication Rate 2 Truism No Advantage to: any Patient for any Radiation
More informationPEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING
PEDIATRIC ORBITAL TUMORS RADIOTHERAPY PLANNING ANATOMY ANATOMY CONT ANATOMY CONT. ANATOMY CONT. EYE OF A CHILD Normal tissue tolerance doses (in conventional #) TD 5/5 TD 50/5 Endpoint Gy Gy Optic nerve
More informationProton therapy for prostate cancer
Proton therapy for prostate cancer Shafak Aluwini Radiation oncologist UMCG Protons versus photons Superior beam properties 200 180 Advantage of protons 160 Photons 140 120 100 Spread out Bragg Peak 80
More information2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA
2007 ANNUAL SITE STUDY HODGKIN S LYMPHOMA SUSQUEHANNA HEALTH David B. Nagel, M.D. April 11, 2008 Hodgkin s lymphoma was first described by Thomas Hodgkin in 1832. It remained an incurable malignancy until
More informationProton and heavy ion radiotherapy: Effect of LET
Proton and heavy ion radiotherapy: Effect of LET As a low LET particle traverses a DNA molecule, ionizations are far apart and double strand breaks are rare With high LET particles, ionizations are closer
More informationRadiation Technology, Hyogo Ion Beam Medical Center, Tatsuno, Hyogo, JAPAN
Analysis of Visual Loss Due to Radiation- Induced Optic Neuropathy After Particle Therapy for Head and Neck and Skull Base Tumors Adjacent to Optic Nerves Y. Demizu 1, M. Murakami 1, D. Miyawaki 1, Y.
More informationDosimetry for Epidemiology Cohorts Who Receive Radiation Therapy
Dosimetry for Epidemiology Cohorts Who Receive Radiation Therapy Wayne Newhauser, PhD Eurados Winter School, Milan, 2016 Introduction About 1 in 2 men and women born today will be diagnosed with some form
More informationEORTC Member Facility Questionnaire
Page 1 of 9 EORTC Member Facility Questionnaire I. Administrative Data Name of person submitting this questionnaire Email address Function Phone Institution Address City Post code Country EORTC No Enter
More informationDemands and Perspectives of Hadron Therapy
Demands and Perspectives of Hadron Therapy Alexander Lin, M.D. Assistant Professor University of Pennsylvania Direction of Operations Roberts Proton Therapy Center Disclosures Teva Pharmaceuticals: Advisory
More informationADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER
ADVANCES IN RADIATION TECHNOLOGIES IN THE TREATMENT OF CANCER Bro. Dr. Collie Miller IARC/WHO Based on trends in the incidence of cancer, the International Agency for Research on Cancer (IARC) and WHO
More informationClinical Aspects of Proton Therapy in Lung Cancer. Joe Y. Chang, MD, PhD Associate Professor
Clinical Aspects of Proton Therapy in Lung Cancer Joe Y. Chang, MD, PhD Associate Professor Clinical Service Chief Thoracic Radiation Oncology Lung Cancer Basic Factors No. 1 cancer killer 161,840 patients
More informationDefining Target Volumes and Organs at Risk: a common language
Defining Target Volumes and Organs at Risk: a common language Eduardo Rosenblatt Section Head Applied Radiation Biology and Radiotherapy (ARBR) Section Division of Human Health IAEA Objective: To introduce
More informationTreatment Planning (Protons vs. Photons)
Treatment Planning Treatment Planning (Protons vs. Photons) Acquisition of imaging data Delineation of regions of interest Selection of beam directions Dose calculation Optimization of the plan Hounsfield
More informationAHSCT in Hodgkin lymphoma - indication and challenges. Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital
AHSCT in Hodgkin lymphoma - indication and challenges Bastian von Tresckow German Hodgkin Study Group Cologne University Hospital AHSCT in Hodgkin Lymphoma The role of AHSCT in HL Mobilisation failure
More informationREVISITING ICRU VOLUME DEFINITIONS. Eduardo Rosenblatt Vienna, Austria
REVISITING ICRU VOLUME DEFINITIONS Eduardo Rosenblatt Vienna, Austria Objective: To introduce target volumes and organ at risk concepts as defined by ICRU. 3D-CRT is the standard There was a need for a
More informationHeavy Ion Tumor Therapy
Heavy Ion Tumor Therapy Applications Bence Mitlasoczki 25.06.2018 Heidelberg 1. Source (H 2 /CO 2 ) 2. Linac 3. Synchrotron 4. Guide 5. Treatment rooms 6. X-ray system 7. Gantry 8. Treatment room with
More informationPotential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana
University of Groningen Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationCardiovascular disease after radiation therapy
Cardiovascular disease after radiation therapy Giovanna Gagliardi Section of Radiotherapy Physics and Engineering Dept. of Medical Physics Karolinska University Hospital, Stockholm EU Scientific Seminar
More informationPeak temperature ratio of TLD glow curves to investigate the spatial variation of LET in a clinical proton beam
Peak temperature ratio of TLD glow curves to investigate the spatial variation of LET in a clinical proton beam University of Chicago CDH Proton Center LET study C. Reft 1, H. Ramirez 2 and M. Pankuch
More informationResults of Stereotactic radiotherapy for Stage I and II NSCLC Is There a Need for Image Guidance?
Results of Stereotactic radiotherapy for Stage I and II NSCLC Is There a Need for Image Guidance? Frank Zimmermann Institute of Radiation Oncolgy University Clinic Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch
More informationMay 8-9, Modern Radiation For Lymphoma. NEW YORK CITY UPDATED ROLE AND NEW RULES
Modern Radiation For Lymphoma May 8-9, 2015 COURSE DIRECTOR Joachim Yahalom MD CHAIRMAN International Lymphoma Radiation Oncology Group MEMBER AND PROFESSOR Memorial Sloan Kettering Cancer Center CONFERENCE
More informationRadiotherapy physics & Equipments
Radiotherapy physics & Equipments RAD 481 Lecture s Title: An Overview of Radiation Therapy for Health Care Professionals Dr. Mohammed Emam Vision :IMC aspires to be a leader in applied medical sciences,
More informationRadiation Therapy 2013 The Role of Protons. Bob Gaston, D.O.
Radiation Therapy 2013 The Role of Protons Bob Gaston, D.O. Disclosures Oklahoma ProCure Treatment Center Radiation Medicine Associates Goal of Radiation Therapy Increase the Therapeutic Ratio Therapeutic
More informationPage 1. Helical (Spiral) Tomotherapy. UW Helical Tomotherapy Unit. Helical (Spiral) Tomotherapy. MVCT of an Anesthetized Dog with a Sinus Tumor
Helical (Spiral) Tomotherapy Novel Clinical Applications of IMRT Linac Ring Gantry CT Detector X-Ray Fan Beam Binary Multileaf Collimator Binary MLC Leaves James S Welsh, MS, MD Department of Human Oncology
More informationPET-imaging: when can it be used to direct lymphoma treatment?
PET-imaging: when can it be used to direct lymphoma treatment? Luca Ceriani Nuclear Medicine and PET-CT centre Oncology Institute of Southern Switzerland Bellinzona Disclosure slide I declare no conflict
More informationLancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma:
1 Lancashire and South Cumbria Haematology NSSG Guidelines for Follicular Lymphoma: 2018-19 1.1 Pretreatment evaluation The following tests should be performed: FBC, U&Es, creat, LFTs, calcium, LDH, Igs/serum
More informationPitfalls and Remedies in PET/CT imaging for RT planning
Pitfalls and Remedies in PET/CT imaging for RT planning Tinsu Pan, Ph.D. M.D. Anderson Cancer Center The University of Texas Outlines Background Average CT (< 1 msv) to reduce mis-alignment of PET and
More informationEvaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer
1 Charles Poole April Case Study April 30, 2012 Evaluation of Whole-Field and Split-Field Intensity Modulation Radiation Therapy (IMRT) Techniques in Head and Neck Cancer Abstract: Introduction: This study
More informationHodgkin. The PET World. Sally Barrington
Hodgkin The PET World Sally Barrington PET-CT Staging in HL PET-CT changes stage 15-30% RATHL - Advanced HL 1171 pts Stage by PET-CT compared with cect and BMB 20% stage change; upstaging 14% Most upstaging
More informationSBRT TREATMENT PLANNING: TIPS + TRICKS. Rachel A. Hackett CMD, RT(T)
SBRT TREATMENT PLANNING: TIPS + TRICKS Rachel A. Hackett CMD, RT(T) OUTLINE Brief radiobiology review 3D CRT Tx Planning VMAT Tx Planning Protocols Other Sites Oligomets Spine Liver Kidney Adrenal Gland
More informationProton Therapy for Prostate Cancer. Andrew K. Lee, MD, MPH Director Proton Therapy Center
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Director Proton Therapy Center Disclosures No relevant financial disclosures This presentation will not discuss off-label or investigational treatments
More informationRadiation treatment planning in lung cancer
Radiation treatment planning in lung cancer Georg Dietmar 1,2 1 Div. Medical Rad. Phys., Dept. of Radiation Oncology / Medical Univ. Vienna & AKH Wien 2 Christian Doppler Laboratory for Medical Radiation
More informationRadiotherapy in aggressive lymphomas. Umberto Ricardi
Radiotherapy in aggressive lymphomas Umberto Ricardi Is there (still) a role for Radiation Therapy in DLCL? NHL: A Heterogeneous Disease ALCL PMLBCL (2%) Burkitt s MCL (6%) Other DLBCL (31%) - 75% of aggressive
More informationProton Therapy: Where Are We Now and Where Are We Going? Erin Davis MSN, CRNP, ACNP BC Lead Nurse Practitioner
Proton Therapy: Where Are We Now and Where Are We Going? Erin Davis MSN, CRNP, ACNP BC Lead Nurse Practitioner Genevieve Hollis MSN, CRNP, ANP-BC, AOCN Oncology Nurse Practitioner Advanced Senior Lecturer-B
More informationMEDICAL MANAGEMENT POLICY
PAGE: 1 of 8 This medical policy is not a guarantee of benefits or coverage, nor should it be deemed as medical advice. In the event of any conflict concerning benefit coverage, the employer/member summary
More informationSpecifics of treatment planning for active scanning and IMPT
Specifics of treatment planning for active scanning and IMPT SFUD IMPT Tony Lomax, Centre for Proton Radiotherapy, Paul Scherrer Institute, Switzerland Treatment planning for scanning 1. Single Field,
More information21 st Century Radiotherapy: State-of-the-art and predicting the future. Clinical applications of PET. PET Imaging
21 st Century Radiotherapy: State-of-the-art and predicting the future Clinical applications of PET Pat Price Ralston Paterson Professor of Radiation Oncology Christie Hospital Manchester UK Mayneord-Phillips
More informationRadiotherapy of Follicular Lymphoma: Updated Role and New Rules
Current Treatment Options in Oncology (2014) 15:262 268 DOI 10.1007/s11864-014-0286-4 Lymphoma (A Engert, Section Editor) Radiotherapy of Follicular Lymphoma: Updated Role and New Rules Joachim Yahalom,
More informationTOMOTERAPIA in Italia: Esperienze a confronto
TOMOTERAPIA in Italia: Esperienze a confronto BARD 20 novembre 2010 L esperienza di Reggio Emilia Testa collo Alessandro Muraglia Reasons for the use of tomotherapy: - Complex tumor geometry and proximity
More informationAccuracy Requirements and Uncertainty Considerations in Radiation Therapy
Departments of Oncology and Medical Biophysics Accuracy Requirements and Uncertainty Considerations in Radiation Therapy Introduction and Overview 6 August 2013 Jacob (Jake) Van Dyk Conformality 18 16
More informationInnovazioni tecnologiche in Radioterapia" Sergio Fersino Radioterapia Oncologica
Innovazioni tecnologiche in Radioterapia" Sergio Fersino Radioterapia Oncologica 2014 HYPOFRACTIONATION & PROSTATE CANCER HYPOFRACTIONATION & PROSTATE CANCER: TECHNOLOGY: HIGH CONFORMAL DOSE & IMAGING
More informationOn behalf of the Israel Cooperative Lymphoma Group. A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler, I. Ben-Bassat and A.
Two cycles of escalated BEACOPP followed by four cycles of ABVD utilizing early-interim PET/CT scan for patients with advanced highrisk Hodgkin s lymphoma A. Avigdor, S. Bulvik, I. Levi, E. Dann, A. Nagler,
More informationAllinaHealthSystems 1
Disclosure Dimensions in Oncology: Radiation Therapy Presenters: Sara Minks BS R.T(T) Carolyn Wall RN, OCN John Smith MS, DABMP Maggie Cunningham BS R.T(T), CMD We have not conflicts of interest to disclose.
More informationDose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed
Dose escalation for NSCLC using conformal RT: 3D and IMRT. Hasan Murshed Take home message Preliminary data shows CRT technique in NSCLC allows dose escalation to an unprecedented level maintaining cancer
More informationFlattening Filter Free beam
Dose rate effect in external radiotherapy: biology and clinic Marta Scorsetti, M.D. Radiotherapy and Radiosurgery Dep., Istituto Clinico Humanitas, Milan, Italy Brescia October 8th/9th, 2015 Flattening
More informationPET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma
PET-adapted therapies in the management of younger patients (age 60) with classical Hodgkin lymphoma Ryan Lynch MD Assistant Professor, University of Washington Assistant Member, Fred Hutchinson Cancer
More informationProton Treatment. Keith Brown, Ph.D., CHP. Associate Director, Radiation Safety University of Pennsylvania
Proton Treatment Keith Brown, Ph.D., CHP Associate Director, Radiation Safety University of Pennsylvania Proton Dose vs. Depth Wilson,. R.R. Radiological use of fast protons. Radiology 47:487-491, 1946.
More informationLinac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR
Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR PhD, FAAPM, FACR, FASTRO Department of Radiation Oncology Indiana University School of Medicine Indianapolis, IN, USA Indra J. Das,
More informationProtons for Head and Neck Cancer. William M Mendenhall, M.D.
Protons for Head and Neck Cancer William M Mendenhall, M.D. Protons for Head and Neck Cancer Potential Advantages: Reduce late complications via more conformal dose distributions Likely to be the major
More informationPotential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana
University of Groningen Potential benefits of intensity-modulated proton therapy in head and neck cancer van de Water, Tara Arpana IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationSubject: Image-Guided Radiation Therapy
04-77260-19 Original Effective Date: 02/15/10 Reviewed: 01/25/18 Revised: 01/01/19 Subject: Image-Guided Radiation Therapy THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More informationRadiotherapy in feline and canine head and neck cancer
Bettina Kandel Like surgery radiotherapy is usually a localized type of treatment. Today it is more readily available for the treatment of cancer in companion animals and many clients are well informed
More informationDeep Inspiration Breath-Hold Techniques: a review of voluntary and controlled breath-hold maneuvers for left-side breast radiation therapy
Deep Inspiration Breath-Hold Techniques: a review of voluntary and controlled breath-hold maneuvers for left-side breast radiation therapy Bo Lu Ph.D. Department of Radiation Oncology University of Florida
More informationI. Equipments for external beam radiotherapy
I. Equipments for external beam radiotherapy 5 linear accelerators (LINACs): Varian TrueBeam 6, 10 & 18 MV photons, 6-18 MeV electrons, image-guided (IGRT) and intensity modulated radiotherapy (IMRT),
More informationIMRT - Intensity Modulated Radiotherapy
IMRT - Intensity Modulated Radiotherapy Advanced product in the RT technology Aims to deliver radiation more precisely to the tumor, while relatively limiting dose to the surrounding normal tissues 7 position
More informationIntegrating the Radixact into a Highly Comprehensive Center
Integrating the Radixact into a Highly Comprehensive Center Alonso N. Gutiérrez, PhD, MBA ASTRO Meeting 2018 Disclosures An honorarium is provided by Accuray for this presentation (donated) Accuray and
More informationNEW 3.0. Manufactured by
NEW 3.0 Manufactured by NEW Lung Patient Decrease Toxicity The SDX System s unique ability to pair a patient s inspiration rate and lung volume measurement with clear visual biofeedback makes it possible
More information